The executive answer
What is the path to yes in life sciences?
The path to yes is the decision architecture that connects the people who recognize a problem, experience its consequences, control resources, evaluate risk, implement the solution and create internal alignment. It makes visible what each person needs to believe before the organization can commit.
How should a technology or service company sell into large pharmaceutical companies?
Begin with one consequential problem and the business leader accountable for solving it. Learn the pharma workflow and define the outcome in that leader’s terms. Then map the full buying coalition, the evidence each group needs, and the approvals and adoption work required to act. Equip a credible internal champion to build a shared case, and measure progress by decisions and commitments from the customer.
The New Enterprise Buying Map™ identifies six constituencies around the purchase. The Path to Yes™ turns that map into an opportunity plan: who has authority, who can block progress, who must implement, what each must believe and who connects them.
- Choose a narrow entry point.Specify the pharma use case, accountable leader, current workflow and cost of inaction.
- Map the buying coalition.Identify business, medical, economic, technology, governance and adoption voices relevant to this decision.
- Build proof for each decision.Connect outcomes, economics, technical fit, risk controls and implementation evidence to the questions each group must resolve.
- Create an internal path to approval.Agree on the next commitment, its owner, decision criteria and the materials your champion needs to align colleagues.
- Review actual movement.Look for cross-functional engagement, resolved objections and customer commitments; redraw the map when the process changes.
When a credible solution, motivated sponsor and apparently strong business case still do not produce movement, the strategy may not be the problem. The organization may be navigating a decision process the commercial team has not fully mapped.
Why linear buying models fail in life sciences
Complex life sciences decisions rarely belong to one buyer. Commercial, medical, market access, procurement, finance, technology, security, legal, compliance and executive leadership can each shape the outcome. Their involvement is not sequential, and their definitions of value and acceptable risk are not interchangeable.
A sponsor can believe in the idea and still be unable to move it. Procurement can reshape the evaluation. Technology can introduce a non-negotiable requirement. An implementation team can quietly resist a decision it must eventually absorb. The visible relationship may be healthy while the internal decision remains stationary.
Decision architecture is more than stakeholder mapping
Stakeholder mapping identifies the people around a decision. Decision architecture explains how the decision moves: who holds authority, who carries consequences, where risk is evaluated, what evidence is required, how dependencies connect and who will do the work of creating alignment.
The distinction matters because a list of names can create false confidence. A decision landscape must show the beliefs and actions that connect those names to a credible collective yes.
The RISE Decision Landscape™
Five gates to a collective yes
Use these questions to expose the real decision system surrounding an opportunity.
Who can say yes?
Identify the people with formal authority to approve the decision and commit resources.
Who can quietly say no?
Surface the stakeholders who can delay, redirect or stop progress without becoming the visible decision-maker.
Who must live with the decision?
Understand the teams responsible for adoption, implementation and ongoing execution.
What must each person believe?
Translate one value proposition into the strategic, financial, operational, clinical and technical proof each audience requires.
Who is creating internal alignment?
Determine whether a credible champion has the influence, evidence and support to move the coalition.
The roles inside a modern decision network
Job titles vary, but consequential decisions typically require several distinct roles. One person may hold more than one role; no role should be assumed merely from seniority.
Problem owner
Recognizes the issue and feels its immediate operational or strategic pressure.
Outcome owner
Is accountable for the result and often controls—or can secure—the investment.
Risk evaluators
Assess clinical, regulatory, financial, legal, privacy, security and reputational exposure.
Adoption owners
Must implement the decision and sustain the resulting change in real work.
Alignment architect
Connects the coalition, translates the case and creates enough confidence for the group to act.
How to apply the RISE Decision Landscape™
- Qualify the decision, not only the opportunity.Define the next consequential commitment, who owns it and what evidence would demonstrate movement.
- Map beliefs as well as people.For each role, document the desired outcome, perceived risk, required proof and unresolved question.
- Locate the constraint.Identify where authority, confidence, priority or implementation capacity is weakest.
- Equip the alignment architect.Give the internal champion language, evidence and a sequence for building support—without asking that person to sell alone.
- Measure organizational movement.Track resolved decisions, new commitments and cross-functional alignment—not only meetings, enthusiasm and content shared.
Signals that the path is weak or outdated
- The team cannot name the next customer decision or its owner.
- Access and enthusiasm are concentrated in one relationship.
- Risk stakeholders appear late and reopen settled assumptions.
- The economic buyer and end user describe value differently.
- The internal champion is carrying the alignment burden without sufficient evidence or influence.
- Pipeline stages advance while customer commitments remain unchanged.
Two sides of the same leadership challenge
For pharma and biotechnology leaders, the framework can clarify decisions involving commercialization partners, technology platforms, data solutions, operating models and enterprise capabilities. It helps teams distinguish vendor activity from organizational readiness to decide.
For solution providers, it shifts the work from persuading a single buyer to helping the customer construct a safer, more relevant and more defensible path to action.
Supporting proof · Ignite Selling
From a broad offer to a clearer enterprise conversation
RISE worked with Ignite Selling to sharpen its life sciences go-to-market approach. The work prioritized emerging pharma and biotechnology launch opportunities, clarified buying moments and decision makers, and organized its strategy, sales process, opportunity planning, customer conversations, coaching and simulation into a Commercial Performance System™. Ignite Selling’s CEO used the system approach in a larger deal conversation, and the partnership continued. This is an example of translating capabilities into a buyer-relevant path; it does not imply that every pharma account follows the same process.
Put the framework to work
Map one consequential decision.
Use the fillable RISE Decision Landscape™ Executive Worksheet to identify the authority, hidden blockers, adoption owners, required beliefs and internal alignment behind a real opportunity.
Download the executive worksheet One-page interactive PDF · Complimentary RISE resourcePrefer to listen? RISE Unpacked Episode 02 explores why promising pharma deals stall and how the buying coalition reaches confidence.
Frequently asked questions
Decision architecture, clarified
How should a technology or service company sell into large pharmaceutical companies?
Start with a specific, consequential pharma problem and the leader accountable for it. Map the cross-functional buying coalition, translate value into the evidence each group needs, plan for risk and implementation reviews, and help an internal champion build a shared case for action. Track customer decisions and commitments rather than meetings alone.
Who is involved in a large pharmaceutical company purchase?
The coalition depends on the use case, but may include commercial or medical business owners, finance and procurement, technology and data, legal and compliance, and the teams that will implement and adopt the solution. The New Enterprise Buying Map™ organizes these perspectives into six constituencies.
What proof does a pharmaceutical buyer need from a technology or service provider?
Show evidence tied to the buyer's workflow and outcome: a credible use case, measurable value or a testable hypothesis, relevant references or pilots when available, data and security fit, compliance readiness, and a realistic implementation plan. Different stakeholders will require different proof.
What is the path to yes in life sciences?
The path to yes is the decision architecture that connects the people who recognize a problem, own its consequences, control resources, evaluate risk, implement the solution and create internal alignment. It shows what must become true for the organization—not only one sponsor—to commit.
How is decision architecture different from stakeholder mapping?
Stakeholder mapping identifies who is involved. Decision architecture explains how the decision moves, where it can stop, what each participant needs to believe and who will create alignment across the group.
Why do promising life sciences opportunities stall?
They often stall because enthusiasm is concentrated in one relationship while authority, risk review, budget control and implementation ownership sit elsewhere. A positive meeting is not the same as organizational movement.
Who should be included in a life sciences decision landscape?
The exact coalition varies, but it commonly includes the problem owner, outcome owner or economic buyer, medical and compliance stakeholders, procurement, finance, technology or security reviewers, implementation owners and an internal alignment architect.
When should a team redraw the decision landscape?
Redraw it when an opportunity stops moving, new risk requirements appear, the sponsor cannot secure support, stakeholders enter late, or the next decision and its owner are unclear.
Put the landscape to work
If a consequential opportunity has stopped moving, RISE can help your team redraw the decision landscape and find the next credible move.
Talk with Carl